Specialist, Quality Control Analytical

1910 Genetics

20n Bio

3DBio Therapeutics

3T Biosciences

4D Molecular Therapeutics

64x Bio

76Bio

A-Alpha Bio

A2 Biotherapeutics

AAVogen

ACELYRIN

AI Proteins

AIRNA Bio

ALX Oncology

AN2 Therapeutics

AOA Dx

ARTBIO

AS2 Bio Inc

AUM BioTech

AVROBIO

Ab Studio

Abalone Bio

Abata Therapeutics

Abeona Therapeutics

Abintus Bio

Abiosciences

Absci

Accelevir Diagnostics

Accent Therapeutics

Acepodia

Achieve Life Sciences

Acomhal Research

Acrivon Therapeutics

Actym Therapeutics, Inc.

Acutis Diagnostics

Adaptive Phage Therapeutics

Adcentrx Therapeutics

Adicet Bio

Adiso Therapeutics

Aditum Bio

Admera Health

Adverum Biotechnologies

Aeglea BioTherapeutics

Aera Therapeutics

Aether Bio

Affini-T Therapeutics

Affinia Therapeutics

Affinivax

AgBiome

Agastiya Biotech

Agena Bioscience

AiViva Biopharma

Ainnocence

AivoCode

Aixa Bio

Akero Therapeutics

Akita Biosciences

Akouos

Akttyva Therapeutics

Alamar Biosciences

Aldebaran Therapeutics

Alector

Alida Biosciences

AlivaMab Discovery Services

Alkahest

Alladapt Immunotherapeutics

Allakos

Allarta Life Science

Allay Therapeutics

AlloVir

Alloy Therapeutics

Alltrna

AlpaLifeBio

Alpha-9 Oncology

Alphabioregen

Alpine Immune Sciences

AltPep

Alterome Therapeutics

Altis Biosystems

Alto Neuroscience

Alumis

Alveo Technologies

Alveolus Bio

Alzheon

AmbAgon Therapeutics

Amberstone Biosciences

Amolyt Pharma

Amylyx Pharmaceuticals

AnHeart Therapeutics

Anagram Therapeutics

Ancora Biotech LLC

Andes

Andson Biotech

Anebulo Pharmaceuticals

Angiex

Angiocrine Bioscience

Anima Biotech

Ankyra

Annexon Biosciences

Anodyne Nanotech

Umoja Biopharma is reprogramming T cells to target cancer cells. Chimeric antigen receptor (CAR) T-cell immunotherapies have shown promising results for hematologic cancers, but the majority of cancers manifest as solid tumors. Umoja is working to create “off-the-shelf” CAR T-cell immunotherapies for patients with solid tumors that are scalable and less expensive than current approaches. To identify effective CAR T-cell gene therapies, Umoja is pioneering complementary solutions to generate cancer fighting T-cells that reduce adverse events and prolong remission for patients. This includes VivoVec, an in vivo gene delivery platform that enables the body to make its own CAR T-cells. Umoja is combining these platforms to build their pipeline, which includes candidates for multiple indications.

<p>Umoja Biopharma is reprogramming T cells to target cancer cells. Chimeric antigen receptor (CAR) T-cell immunotherapies have shown promising results for hematologic cancers, but the majority of cancers manifest as solid tumors. Umoja is working to create “off-the-shelf” CAR T-cell immunotherapies for patients with solid tumors that are scalable and less expensive than current approaches. To identify effective CAR T-cell gene therapies, Umoja is pioneering complementary solutions to generate cancer fighting T-cells that reduce adverse events and prolong remission for patients. This includes VivoVec, an in vivo gene delivery platform that enables the body to make its own CAR T-cells. Umoja is combining these platforms to build their pipeline, which includes candidates for multiple indications.</p>


Find a biotech startup job.